Programs

You are here

Lanthi-angiotensins

Endogenous overstimulation of the so-called detrimental arm of the Renin-Angiotensin System (RAS) plays an important role in the initiation and progression of cardiovascular, renal and other diseases. In contrast, stimulation of so-called protective RAS, especially AT2- or Mas receptors, may counterbalance the detrimental effects and offers a novel strategy for treatment of diseases with high unmet medical need. Lanthio Pharma has discovered lanthionine-constrained agonists of the protective RAS receptors, subject of three development programs.

Lanthi-apelins

Apelins are the endogenous peptide ligands for the APJ receptor. Lanthio Pharma has discovered highly active and stable lanthi-apelins that differentially stimulate APJ-receptor–coupled intracellular pathways (biased agonism).

Lanthi-galanin

Natural galanin acts via three different receptor subtypes, GalR1, GalR2 and GalR3. Lanthio Pharma has discovered lanthi-galanins with enhanced subtype receptor specificities.